The association between statin use and outcomes in patients initiating androgen deprivation therapy.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 145-145 ◽  
Author(s):  
Robert James Hamilton ◽  
Keyue Ding ◽  
Juanita M. Crook ◽  
Christopher J. O'Callaghan ◽  
Celestia S. Higano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Statistical Significance ◽  
Prospective Trial ◽  
Androgen Deprivation ◽  
Castration Resistance ◽  
Cancer Specific Survival ◽  
Statin Use

145 Background: Studies are conflicting regarding the association between statin use and biochemical recurrence after surgery or radiotherapy for localized prostate cancer. A handful of studies have observed favorable associations between statins and prostate cancer-specific (PCSM) and overall mortality (OS), however, this has not been studied in an advanced disease cohort nor has the combination of statins and androgen deprivation therapy (ADT) been specifically studied. Methods: Patients with PSA >3 ng/mL after >1 year following primary or salvage radiotherapy (RT) were enrolled in a randomized trial of intermittent (IAD) vs. continuous (CAD) ADT (NCT00003653). Statin use at baseline and during the study was captured and modeled as a time-dependent covariate. The primary end-point was OS. Models were adjusted for age, time from RT to ADT and PSA at baseline. As results were nearly identical between the IAD and CAD arms they are reported as aggregates unless otherwise indicated. Results: Of 1,364 patients enrolled, 585 (43%) reported statin use during the study. Statin users were younger (72.7 vs. 73.8, p=0.001) and less likely to have PSA >15 (20 vs. 25%, p=0.04). Median follow-up was 6.9 years and 524 deaths occurred. Statin use was associated with a reduced risk of overall death (HR: 0.64; 95% C.I. 0.53 – 0.78, p<0.001) and PCSM (HR: 0.64, 95% C.I. 0.48 – 0.86, p=0.003). Statin users had 14% longer time to castration resistance but this did not reach statistical significance (p=0.15). In the IAD arm, statin users had more off-treatment intervals (p=0.04) and longer time off-treatment (median: 0.85 vs. 0.64 years, p=0.06). Across 6 functional domains, statin users reported better quality of life scores. Conclusions: In men treated with ADT following primary or salvage RT, statin use was associated with improved overall and prostate cancer-specific survival and improved quality of life. In patients treated with IAD, statin use was associated with more off-treatment intervals and longer time off-treatment. A prospective trial of statins in men commencing ADT is warranted to confirm this observation.

Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy

2013 ◽  
Vol 22 (10) ◽  
pp. 2169-2176 ◽  
Author(s):  
Kelly Chipperfield ◽  
Jane Fletcher ◽  
Jeremy Millar ◽  
Joanne Brooker ◽  
Robin Smith ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Predictors Of Depression

Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life

2010 ◽  
Vol 7 (9) ◽  
pp. 2996-3010 ◽  
Author(s):  
Stacy Elliott ◽  
David M. Latini ◽  
Lauren M. Walker ◽  
Richard Wassersug ◽  
John W. Robinson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Improve Patient

Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review

2014 ◽  
Vol 32 (4) ◽  
pp. 335-346 ◽  
Author(s):  
Jason R. Gardner ◽  
Patricia M. Livingston ◽  
Steve F. Fraser
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Adverse Effects ◽  
Androgen Deprivation Therapy ◽  
Bone Health ◽  
Cardiometabolic Risk ◽  
Androgen Deprivation ◽  
Cochrane Library

Purpose Androgen-deprivation therapy is a commonly used treatment for men with prostate cancer; however, the adverse effects can be detrimental to patient health and quality of life. Exercise has been proposed as a strategy for ameliorating a range of these treatment-related adverse effects. We conducted a systematic review of the literature regarding the effects of exercise on treatment-related adverse effects in men receiving androgen-deprivation therapy for prostate cancer. Methods An online electronic search of the Cochrane Library, EMBASE, MEDLINE, CINAHL, SPORTDiscus, and Health Source databases was performed to identify relevant peer-reviewed articles published between January 1980 and June 2013. Eligible study designs included randomized controlled trials as well as uncontrolled trials with pre- and postintervention data. Information was extracted regarding participant and exercise intervention characteristics as well as the effects of exercise on bone health, body composition, physical performance, cardiometabolic risk, fatigue, and quality of life. Results Ten studies were included, with exercise interventions involving aerobic and/or resistance training. Exercise training demonstrated benefits in muscular strength, cardiorespiratory fitness, functional task performance, lean body mass, and fatigue, with inconsistent effects observed for adiposity. The impact of exercise on bone health, cardiometabolic risk markers, and quality of life are currently unclear. Conclusion Among patients with prostate cancer treated with androgen-deprivation therapy, appropriately prescribed exercise is safe and may ameliorate a range of treatment-induced adverse effects. Ongoing research of high methodologic quality is required to consolidate and expand on current knowledge and to allow the development of specific evidence-based exercise prescription recommendations.

Sexuality and Intimacy After Definitive Treatment and Subsequent Androgen Deprivation Therapy for Prostate Cancer

2012 ◽  
Vol 30 (30) ◽  
pp. 3720-3725 ◽  
Author(s):  
Celestia S. Higano
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Large Population ◽  
The United States ◽  
Androgen Deprivation ◽  
Definitive Treatment ◽  
Primary Therapy ◽  
Prostate Cancer Survivors

There are more than 2 million prostate cancer survivors in the United States. Primary therapy with surgery or radiation results in permanent changes in sexual function. More than half of these men are subsequently treated with androgen deprivation therapy (ADT) at some point. The addition of ADT further compromises sexuality, intimacy, and a couple's relationship. This review will highlight the challenges faced by patients and couples and reveal the tremendous need for better education of physicians, patients, and couples as well as for more research in sexuality and intimacy with the goal of improving quality of life for this large population of survivors. Suggestions for clinicians to better help patients and their partners regarding sexuality and intimacy are offered.

Sign in / Sign up

Export Citation Format

Share Document